**The ALINA trial: ALECENSA as an adjuvant treatment in early-stage ALK + NSCLC¹**

ALINA is a global, open-label, Phase III, randomized trial investigating the efficacy and safety of adjuvant ALECENSA vs. platinum-based chemotherapy.¹

Primary endpoint: Disease-free survival^‡

Secondary endpoints: OS and safety

Exploratory endpoints: CNS disease-free survival^§

*Per UICC/AJCC 7th edition. †Cisplatin + pemetrexed, cisplatin + vinorelbine or cisplatin + gemcitabine; cisplatin could be switched to carboplatin in case of intolerability. ‡Defined as the time from randomization to the first documented recurrence of disease or new primary NSCLC as determined by the investigator or death from any cause §Defined as time from randomization to the first documented recurrence of disease in the CNS or death from any cause.¹

AJCC, American Joint Committee on Cancer; ALK, anaplastic lymphoma kinase; BID PO, twice a day orally; CNS, central nervous system; ECOG PS, Eastern Cooperative Oncology Group Performance Status; NSCLC, non-small-cell lung cancer; OS, overall survival; R, randomization; TKI, tyrosine kinase inhibitor; UICC, Union for International Cancer Control.

1. Wu YL, et al. N Engl J Med. 2024;390:1265–1276.

This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration, or usage in the country of your origin.

Characteristic	ALECENSA (n=130)
Median age, years < 65 years old / ≥65 years old, %	54 79 / 21
Sex: female / male, %	58 / 42
Smoking status: never / former / current, %	65 / 32 / 4
Race: Asian / non-Asian, %	55 / 45
ECOG PS: 0 / 1, %	55 / 45
Stage at diagnosis:* IB / II / IIIA, %	11 / 36 / 53
Nodal status: N0 / N1 / N2, %	16 / 35 / 49
Histology: squamous / non-squamous, %	5 / 95
Surgical procedure: Lobectomy / other,^¶ %	97 / 3

Characteristic	Chemotherapy (n=127)
Median age, years < 65 years old / ≥65 years old, %	57 73 / 27
Sex: female / male, %	47 / 54
Smoking status: never / former / current, %	55 / 43 / 2
Race: Asian / non-Asian, %	56 / 46
ECOG PS: 0 / 1, %	51 / 49
Stage at diagnosis:* IB / II / IIIA, %	9 / 35 / 55
Nodal status: N0 / N1 / N2, %	14 / 34 / 52
Histology: squamous / non-squamous, %	2 / 98
Surgical procedure: Lobectomy / other,^¶ %	92 / 8

Characteristic	ALECENSA (n=130)	Chemotherapy  (n=127)
Median age, years <65 years old / ≥65 years old, %	54 79 / 21	57 73 / 27
Sex: female / male, %	58 / 42	47 / 54
Smoking status: never / former / current, %	65 / 32 / 4	55 / 43 / 2
Race: Asian / non-Asian, %	55 / 45	56 / 44
ECOG PS: 0 / 1, %	55 / 45	51 / 49
Stage at diagnosis:* IB / II / IIIA, %	11 / 36 / 53	9 / 35 / 55
Nodal status: N0 / N1 / N2, %	16 / 35 / 49	14 / 34 / 52
Histology: squamous / non-squamous, %	5 / 95	2 / 98
Surgical procedure: Lobectomy / other,^¶ %	97 / 3	92 / 8

FOR HEALTHCARE PROFESSIONALS

Leaving website

**The ALINA trial: ALECENSA as an adjuvant treatment in early-stage ALK + NSCLC¹**

Discover

Explore

FOR HEALTHCARE PROFESSIONALS

Leaving website

The ALINA trial: ALECENSA as an adjuvant treatment in early-stage ALK + NSCLC1

ALINA: Patient demographics and baseline characteristics (ITT)2

Discover

Explore

**The ALINA trial: ALECENSA as an adjuvant treatment in early-stage ALK + NSCLC¹**

ALINA: Patient demographics and baseline characteristics (ITT)²